查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808376

按产品类型、技术、应用和最终用户照护现场诊断分子诊断市场 - 全球预测 2025-2030

Point of Care Molecular Diagnostics Market by Product Type, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计照护现场诊断市场规模到 2024 年将达到 52.6 亿美元，到 2025 年将达到 56.4 亿美元，到 2030 年将达到 80.9 亿美元，复合年增长率为 7.42%。

主要市场统计数据
基准年2024年 52.6亿美元
预计2025年 56.4亿美元
预测年份 2030 80.9亿美元
复合年增长率（%） 7.42%

利用快速的即时分子诊断技术，增强即时临床决策能力，为以患者为中心的医疗照护的未来铺平道路

即时诊断 (POC) 分子诊断技术正在透过快速、准确、分散式检查，彻底改变患者照护的模式。微型核酸扩增系统的引入，加上数位化连接，正在加速从集中式实验室转向床边检测环境的转变。这种转变使临床医生能够在需要时做出明智的决策，从而缩短週转时间并优化治疗方案。

随着技术创新和医疗保健服务模式的变化，POC分子诊断正在快速发展

近年来，科技取得了显着进步，重塑了即时诊断 (POC) 分子诊断生态系统。微流体晶片设计和试剂配方的创新显着缩短了检测週转时间，使关键决策能够在几分钟内而非几小时内做出。同时，可携式硬体与云端基础资料平台的集成，实现了分散式检查站点与中心实验室网路之间的无缝连接。因此，临床医生可以即时获得可操作的检测结果、患者病史和群体健康指标。

评估 2025 年美国关税对即时分子诊断供应链和成本结构的累积影响

2025年美国加征关税为即时诊断（POC）分子诊断试剂的供应商和最终用户带来了新的挑战。检测仪器以及耗材试剂和套件都面临进口关税上调，这将直接影响成本结构。为此，製造商正在加快在地化生产和签订替代采购协议的步伐，以降低利润率下降的风险。

根据产品类型、技术应用和最终用户，揭示照护现场分子诊断市场的关键细分洞察

全面审视产品类型后发现，在设计和便携性持续创新的推动下，仪器销售仍是平台普及的关键。同时，随着检测项目扩展至多重检测组合和新型生物标记物，试剂和套件的需求仍然强劲。同时，由于实验室和医疗网路更注重数据分析和无缝互通性而非独立硬件，软体产品也越来越受欢迎。

了解影响 POC 在美洲、中东/非洲和亚太地区传播的区域动态

在美洲，持续的医疗基础设施投资和有利的法规环境正在加速POC在都市区地区的普及。联邦政府为加强疫情防控倡议，已为快速检测的开发提供了资金，而私人医疗网络则持续扩展门诊和社区健康中心的照护现场能力。

揭示透过伙伴关係、合併和产品开发推动即时分子诊断创新的关键参与者的策略性倡议

产业领导者正优先考虑策略联盟和收购，以扩大照护现场分子诊断产品组合。主要的诊断开发商正在与专业试剂製造商合作，共同开发专有的检测化学方法，并简化伙伴关係链。同时，许多公司宣布对软体分析公司进行补充收购，以增强其在分散式检测网路中的资料整合能力。

为行业领导者制定可行的建议，以利用即时分子诊断的机会并增强其竞争优势

为了满足日益增长的快速分子检测需求，产业领导者应投资于支援模组化检测扩展的灵活平台架构。设计能够相容于各种试剂盒的系统，使公司能够快速应对新出现的病原体威胁和不断变化的临床重点。同样重要的是与试剂製造商建立策略合作伙伴关係，以确保可靠的高品质化学品供应。

了解我们严谨的调查方法，这些方法支撑我们全面、可靠的 POC 分子诊断洞察分析

此项分析基于严谨的研究框架，结合了对多个地区的高阶主管、实验室主任和临床终端使用者的深入访谈。这些访谈提供了关于采用驱动因素、技术偏好以及 POC 应用特有的营运挑战的第一手见解。

关于照护现场诊断在现代医疗保健中的变革潜力和策略重要性的总结性观点

照护现场。随着平台变得更加紧凑、用户友好和数位互联，它们有可能重新定义诊断工作流程，并改善各种医疗环境中的患者治疗效果。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 将基于 CRISPR 的检测方法整合到可携式照护现场平台中，以快速识别病原体
  • 推出支援智慧型手机的分子诊断设备，用于分散式患者检测
  • 在照护现场分子诊断结果解释中实施人工智慧驱动的预测分析
  • 扩大多重PCR检测规模，以便在护理点同时检测多种感染疾病
  • 开发等温扩增技术，实现低成本、现场可部署的分子侦测解决方案
  • 监管部门的核准加速了下一代基于墨盒的分子诊断系统的商业化
  • 诊断公司与远端医疗提供者合作简化远距分子检测工作流程
  • 用于家庭感染疾病监测和管理的家用分子检测套组的成长
  • 新兴的纸基微流体平台，用于资源有限环境下的超低成本即时分子诊断
  • 门诊和分散护理机构对快速肿瘤生物标记检测的需求不断增加

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8照护现场诊断分子诊断市场（依产品类型）

  • 装置
  • 试剂和套件
  • 软体

第九章照护现场分子诊断市场（按技术）

  • 基于基因序列
  • 杂交基地
  • 恒温核酸增幅技术（INAAT）
  • 基于微阵列
  • 基于PCR

第 10 章。照护现场分子诊断市场（按应用）

  • 心臟病学
  • 基因检测
    • 携带者筛检
    • 新生儿筛检
    • 产前检查
  • 感染疾病
    • 胃肠道感染疾病
    • 呼吸道感染疾病
    • 性行为感染传染病
    • 热带疾病
  • 肿瘤学
    • 液态生物检体
    • 突变分析
    • 肿瘤基因面板

第 11 章。照护现场分子诊断市场（按最终用户）

  • 诊所
  • 诊断实验室
  • 居家照护环境
  • 医院

12. 美国照护现场诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 欧洲、中东和非洲照护现场诊断市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

14. 亚太地区照护现场分子诊断市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • ACON LABS INC.
    • Binx Health, inc.
    • bioMerieux SA
    • Cardinal Health, Inc.
    • Chembio Diagnostics Inc.
    • Co-Diagnostics, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • EKF Diagnostics Holdings
    • FHoffmann-La Roche AG
    • Genomadix Inc. by LuminUltra Technologies Ltd.
    • Henry Schein, Inc.
    • Meridian Bioscience, Inc.
    • Novartis AG
    • OraSure Technologies, Inc.
    • Pfizer, Inc.
    • QIAGEN NV
    • Quidel Corporation
    • SD Biosensor
    • Sekisui Diagnostics
    • SHUWEN BIOTECH CO., LTD
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

Product Code: MRR-5A2C6AA669BE

The Point of Care Molecular Diagnostics Market was valued at USD 5.26 billion in 2024 and is projected to grow to USD 5.64 billion in 2025, with a CAGR of 7.42%, reaching USD 8.09 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.26 billion
Estimated Year [2025] USD 5.64 billion
Forecast Year [2030] USD 8.09 billion
CAGR (%) 7.42%

Unlocking the Future of Patient-Centered Care Through Rapid Point of Care Molecular Diagnostics That Enhance Clinical Decision Making Across Healthcare Settings

Point of care molecular diagnostics is transforming the delivery of patient care by enabling rapid, accurate, and decentralized testing. The introduction of miniaturized nucleic acid amplification systems combined with digital connectivity has accelerated the shift from centralized laboratories to bedside testing environments. This transition empowers clinicians to make informed decisions at the point of need, reducing turnaround times and optimizing treatment pathways.

Emerging assay formats leverage isothermal amplification, microfluidics, and integrated cartridge-based workflows to simplify sample preparation and analysis. As a result, healthcare professionals can detect infectious pathogens, genetic mutations, and oncological biomarkers in a fraction of the time required by traditional laboratory platforms. This evolution aligns with the broader trend toward personalized medicine, where diagnostic insights drive targeted therapies and improve clinical outcomes.

Furthermore, evolving reimbursement frameworks and regulatory guidelines have catalyzed the adoption of these devices in diverse care settings. Strategic collaborations between diagnostic developers, healthcare institutions, and digital health companies are fostering interoperability and data integration, creating an ecosystem that supports real-time surveillance and longitudinal patient monitoring.

The lessons learned from global pandemic responses have underscored the critical importance of rapid molecular detection in controlling outbreaks and mitigating public health risks. By deploying portable diagnostic units in field settings and resource-limited environments, stakeholders can identify and contain emerging threats before they spread. Consequently, this capability not only enhances the resilience of healthcare systems but also supports broader public health initiatives aimed at disease surveillance and prevention.

Charting the Rapid Evolution of Point of Care Molecular Diagnostics Driven by Technological Innovation and Shifting Healthcare Delivery Models

Recent years have witnessed remarkable technological advances that are reshaping the point of care molecular diagnostics ecosystem. Innovations in microfluidic chip design and reagent formulation have dramatically reduced assay turnaround times, allowing critical decisions to be made within minutes rather than hours. Simultaneously, the integration of portable hardware with cloud-based data platforms is enabling seamless connectivity between decentralized test sites and central laboratory networks. As a result, clinicians benefit from immediate access to actionable test results alongside patient histories and population health metrics.

Concurrently, the rise of machine learning and artificial intelligence has begun to inform assay interpretation and workflow optimization. Predictive algorithms can now help flag inconsistent assay outputs, standardize quality control, and even suggest differential diagnoses based on molecular signatures. These capabilities not only improve analytical accuracy but also reduce the burden on healthcare professionals, who face increasing pressures related to staffing shortages and rising case volumes.

Regulatory bodies and payers are responding to these shifts by streamlining approval pathways and updating reimbursement codes to reflect the value proposition of rapid molecular assays. In parallel, healthcare systems are exploring value-based care models that incentivize the reduction of hospital stays and readmissions through timely diagnostics. Taken together, these transformative forces are charting a new era in which point of care molecular testing becomes an indispensable component of efficient, patient-centered healthcare delivery.

Assessing the Cumulative Impact of 2025 United States Tariff Measures on Point of Care Molecular Diagnostics Supply Chains and Cost Structures

The imposition of enhanced tariff measures by the United States in 2025 has introduced a new set of challenges for suppliers and end users of point of care molecular diagnostics. Instruments, along with their consumable reagents and kits, are facing increased import duties that directly impact cost structures. In response, manufacturers are accelerating efforts to localize production and secure alternative sourcing agreements, thereby mitigating the risk of margin erosion.

As reagents become subject to higher duties, distributors and diagnostic laboratories are reevaluating inventory strategies and pricing models. Some organizations have begun renegotiating long-term contracts to achieve volume-based discounts or to shift toward vendor-managed inventory solutions that reduce holding costs. Despite these adjustments, smaller clinics and home care providers may experience delayed adoption of new assays due to constrained budgets and tighter procurement cycles.

Yet, amid these headwinds, a silver lining has emerged: renewed interest in domestic supply chain resilience. Stakeholders are exploring partnerships with contract manufacturing organizations and establishing regional distribution hubs to shorten lead times and reduce exposure to global logistics disruptions. Ultimately, the 2025 tariff environment is prompting a strategic realignment across the value chain as industry participants strive to balance cost pressures against the imperative for rapid, reliable molecular diagnostics.

Illuminating Key Segmentation Insights Across Product Types Technologies Applications and End Users in the Point of Care Molecular Diagnostics Market

A comprehensive examination of product categories reveals that instrument sales continue to serve as a cornerstone for platform adoption, driven by ongoing innovations in design and portability. At the same time, reagents and kits are experiencing robust demand as assay menus expand to include multiplex panels and novel biomarkers. Software offerings, meanwhile, are gaining traction as laboratories and care networks prioritize data analytics and seamless interoperability over standalone hardware.

When analyzing technological underpinnings, genetic sequencing-based approaches have begun to penetrate the point of care arena by offering comprehensive genomic insights in near real time. Hybridization-based methods maintain their stronghold in targeted applications, while isothermal nucleic acid amplification technology provides cost-effective, rapid detection in resource-constrained environments. Furthermore, microarray-based solutions are carving out niches in specialized diagnostics, and PCR-based platforms remain the predominant choice for high-sensitivity assays.

In terms of clinical applications, cardiology assays are emerging as a critical tool for identifying acute cardiac events and guiding treatment pathways. Genetic testing has diversified beyond traditional carrier screening to encompass newborn and prenatal diagnostics, delivering actionable information earlier in the patient journey. Infectious disease testing continues to evolve with expanded panels for gastrointestinal, respiratory, sexually transmitted, and tropical pathogens. Oncology has witnessed significant growth in liquid biopsy techniques, mutation profiling, and onco-gene panels that support personalized cancer management.

Finally, end user dynamics underscore a shift toward decentralized models. Clinics are investing in compact systems to deliver same-visit results, whereas diagnostic laboratories reinforce centralized capabilities with point of care extensions. Home care settings are piloting user-friendly devices that enable remote monitoring, and hospitals are integrating molecular diagnostics into emergency and surgical workflows to enhance patient throughput.

Revealing Regional Dynamics Shaping Adoption of Point of Care Molecular Diagnostics Across the Americas Europe Middle East and Africa and Asia-Pacific

In the Americas, sustained investment in healthcare infrastructure and a supportive regulatory environment have accelerated the deployment of point of care molecular diagnostics across both urban and rural settings. Federal initiatives aimed at strengthening pandemic preparedness have unlocked funding for rapid test development, while private healthcare networks continue to expand point of care capabilities within ambulatory care and community health centers.

Across Europe Middle East and Africa, diverse regulatory landscapes present both challenges and opportunities. In Western Europe, harmonized approval processes and robust reimbursement schemes have fostered early adoption of advanced molecular platforms. Meanwhile, in emerging markets, flexible pricing models and public-private partnerships are instrumental in scaling assay deployment. Regions facing infrastructure limitations are increasingly leveraging portable, battery-powered devices to bridge diagnostic gaps.

Asia-Pacific is witnessing some of the fastest growth rates globally, fueled by large patient populations and proactive government initiatives focused on disease surveillance. Economic growth in key markets has led to enhanced healthcare spending, while innovative payment models-such as subscription-based reagent plans-are unlocking access in mid-tier hospitals and clinics. Additionally, collaborations with local manufacturers are reducing costs and expediting market entry for new assays.

Uncovering Strategic Moves of Leading Players Driving Innovation in Point of Care Molecular Diagnostics Through Partnerships Mergers and Product Development

Leading industry participants are prioritizing strategic collaborations and acquisitions to broaden their point of care molecular diagnostics portfolios. Major diagnostic developers are forging partnerships with specialty reagent producers to co-develop proprietary assay chemistries and streamline supply chains. Simultaneously, a number of players have announced bolt-on acquisitions of software analytics firms to elevate data integration capabilities across decentralized testing networks.

On the innovation front, several organizations are piloting next-generation sequencing modules that can be tethered to mobile workstations, thereby bringing comprehensive genomic profiling to outpatient settings. Other companies are doubling down on isothermal amplification technology, aiming to deliver low-cost, high-throughput solutions amenable to field deployment in emerging markets. Across the board, differentiated assay sensitivity and specificity have become key competitive levers.

Moreover, an increasing emphasis on digital health has prompted diagnostic vendors to bundle connectivity services, offering cloud-based result management and remote quality-control dashboards. This shift is reshaping go-to-market strategies as customers demand turnkey solutions that encompass hardware, consumables, and software under unified service agreements.

Formulating Actionable Recommendations for Industry Leaders to Capitalize on Opportunities in Point of Care Molecular Diagnostics and Enhance Competitive Advantage

To capitalize on the growing demand for rapid molecular testing, industry leaders should invest in flexible platform architectures that support modular assay expansion. By designing systems capable of accommodating a wide range of reagent cartridges, organizations can swiftly respond to emerging pathogen threats and shifting clinical priorities. Equally important is the cultivation of strategic alliances with reagent manufacturers to ensure a reliable supply of high-quality chemistries.

Furthermore, aligning product development roadmaps with evolving regulatory frameworks and reimbursement pathways will expedite market access. Cross-functional task forces that include regulatory experts, clinical liaisons, and health economics professionals can proactively address compliance requirements and articulate value propositions to payers. In parallel, establishing training programs and remote support capabilities will enhance user adoption and minimize operator errors in decentralized environments.

Finally, enhancing supply chain resilience through the localization of key manufacturing processes and the creation of regional distribution hubs will mitigate the impact of future trade disruptions. Coupling these efforts with data-driven demand forecasting tools will optimize inventory levels and reduce lead times. By adopting these measures, decision-makers can secure a competitive edge while delivering reliable point of care diagnostics to a broad spectrum of end users.

Detailing the Rigorous Research Methodology Underpinning the Analysis for Comprehensive and Reliable Point of Care Molecular Diagnostics Insights

This analysis is grounded in a rigorous research framework that combines in-depth primary interviews with senior executives, laboratory directors, and clinical end users across multiple geographies. These conversations provided first-hand insights into adoption drivers, technology preferences, and operational challenges specific to point of care molecular applications.

Secondary research complemented these qualitative findings by drawing on peer-reviewed publications, regulatory filings, and corporate release documents. Data from industry whitepapers and public health agency reports were triangulated against proprietary databases to validate trends and ensure consistency. Each data point underwent cross-verification through multiple sources to maintain accuracy and objectivity.

Our segmentation approach aligns product types, technology modalities, clinical applications, and end user categories to deliver a nuanced understanding of market dynamics. Regional analyses were informed by economic indicators, healthcare spending patterns, and local regulatory landscapes. Key performance metrics and thematic insights were further tested through scenario planning exercises to assess resilience under varying market conditions.

Quality control measures-including independent peer reviews, editorial audits, and methodological sanity checks-ensure that findings meet the highest standards of reliability. The resulting perspectives offer stakeholders a robust foundation for strategic decision-making and informed investment in point of care molecular diagnostics.

Concluding Perspectives on the Transformative Potential and Strategic Imperatives of Point of Care Molecular Diagnostics in Modern Healthcare

Point of care molecular diagnostics stands at the intersection of technological innovation, clinical necessity, and economic pragmatism. As platforms become more compact, user friendly, and digitally connected, they have the potential to redefine diagnostic workflows and enhance patient outcomes across diverse care settings.

Industry participants must remain vigilant in adapting to shifting regulatory requirements, supply chain challenges, and evolving reimbursement landscapes. By embracing strategic partnerships, investing in modular architectures, and aligning closely with clinical stakeholders, organizations can harness the transformative power of rapid molecular testing. Ultimately, those who proactively integrate these solutions into healthcare delivery models will lead the migration toward faster, more personalized care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of CRISPR-based detection methods into portable point-of-care platforms for rapid pathogen identification
  • 5.2. Adoption of smartphone-enabled molecular diagnostic devices for decentralized patient testing
  • 5.3. Implementation of AI-driven predictive analytics in point-of-care molecular diagnostic result interpretation
  • 5.4. Expansion of multiplex PCR assays for simultaneous detection of multiple infectious diseases at point of care
  • 5.5. Development of isothermal amplification technologies for low-cost, field-deployable molecular testing solutions
  • 5.6. Regulatory approvals accelerating commercialization of next-generation cartridge-based molecular diagnostic systems
  • 5.7. Partnerships between diagnostics firms and telehealth providers to streamline remote molecular testing workflows
  • 5.8. Growth of home-based molecular testing kits for at-home infectious disease monitoring and management
  • 5.9. Emergence of paper-based microfluidic platforms for ultra-low-cost point-of-care molecular diagnostics in resource-limited settings
  • 5.10. Increasing demand for rapid oncology biomarker assays in outpatient clinics and decentralized care settings

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Molecular Diagnostics Market, by Product Type

  • 8.1. Introduction
  • 8.2. Instruments
  • 8.3. Reagents & Kits
  • 8.4. Software

9. Point of Care Molecular Diagnostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Genetic Sequencing-based
  • 9.3. Hybridization-based
  • 9.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 9.5. Microarray-based
  • 9.6. PCR-based

10. Point of Care Molecular Diagnostics Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiology
  • 10.3. Genetic Testing
    • 10.3.1. Carrier Screening
    • 10.3.2. Newborn Screening
    • 10.3.3. Prenatal Testing
  • 10.4. Infectious Disease
    • 10.4.1. Gastrointestinal Infections
    • 10.4.2. Respiratory Infections
    • 10.4.3. Sexually Transmitted Infections
    • 10.4.4. Tropical Diseases
  • 10.5. Oncology
    • 10.5.1. Liquid Biopsy
    • 10.5.2. Mutation Profiling
    • 10.5.3. Oncogene Panel

11. Point of Care Molecular Diagnostics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Home Care Settings
  • 11.5. Hospitals

12. Americas Point of Care Molecular Diagnostics Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Point of Care Molecular Diagnostics Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Point of Care Molecular Diagnostics Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Becton, Dickinson and Company
    • 15.3.3. ACON LABS INC.
    • 15.3.4. Binx Health, inc.
    • 15.3.5. bioMerieux SA
    • 15.3.6. Cardinal Health, Inc.
    • 15.3.7. Chembio Diagnostics Inc.
    • 15.3.8. Co-Diagnostics, Inc.
    • 15.3.9. Danaher Corporation
    • 15.3.10. DiaSorin S.p.A
    • 15.3.11. EKF Diagnostics Holdings
    • 15.3.12. FHoffmann-La Roche AG
    • 15.3.13. Genomadix Inc. by LuminUltra Technologies Ltd.
    • 15.3.14. Henry Schein, Inc.
    • 15.3.15. Meridian Bioscience, Inc.
    • 15.3.16. Novartis AG
    • 15.3.17. OraSure Technologies, Inc.
    • 15.3.18. Pfizer, Inc.
    • 15.3.19. QIAGEN N.V.
    • 15.3.20. Quidel Corporation
    • 15.3.21. SD Biosensor
    • 15.3.22. Sekisui Diagnostics
    • 15.3.23. SHUWEN BIOTECH CO., LTD
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Sysmex Corporation
    • 15.3.26. Thermo Fisher Scientific Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 24. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 25. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 26. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 125. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 142. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 143. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 144. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 145. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 146. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 155. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 156. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 157. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 158. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 159. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 161. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 197. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 199. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 200. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 201. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 202. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 203. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 205. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 211. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 215. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 216. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 217. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 219. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 228. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 229. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 230. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 231. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 233. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 239. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 241. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 243. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 244. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 245. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 253. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 255. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 256. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 257. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 258. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 259. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 284. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 286. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 287. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 289. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)

TABLE 29